Nadolol for Proliferating Infantile Hemangiomas: A Prospective Open Label Study With a Historical Control
Systemic corticosteroids are currently the most frequent used medication for treatment of
problematic infantile hemangiomas (IH's). Since June 2008, systemic propranolol has been an
important addition to the therapeutic options for problematic IH, allowing decreased
dependence on the systemic corticosteroids. So far, we have found excellent response with
propranolol with minimal short-term side effects. Studies, which compared nadolol and
propranolol in children with other conditions, suggest that nadolol is safer and more
efficacious than propranolol. In addition, it has better dosing schedules and less central
nervous system (CNS) penetration, making it suitable even for patients with suspected or
proven PHACES syndrome.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Proportion of subjects with at least 75% improvement in the extent of the hemangioma
Baseline, 6months
No
Elena Pope, MD
Principal Investigator
The Hospital for Sick Children
Canada: Health Canada
1000014079
NCT01010308
November 2009
February 2012
Name | Location |
---|